Analysis of "Broad Spectrum" UVA and UVB Components in Sun Care Products for Compliance with New FDA Regulations
The Application Notebook
The FDA has made changes to how products containing sunscreen are labeled in the U.S. to ensure they meet the new regulations set forth for safety and effectiveness. The new regulations will require companies that want to use the "broad spectrum" label to test for both UVA and UVB protection.
The FDA has made changes to how products containing sunscreen are labeled in the U.S. to ensure they meet the new regulations set forth for safety and effectiveness. The new regulations will require companies that want to use the "broad spectrum" label to test for both UVA and UVB protection. Previous regulations only dealt with preventing sunburn which is primarily due to UVB radiation but did not address UVA which protects against early aging and skin cancer. All products that claim to provide broad spectrum SPF protection are regulated as sunscreen products. Therefore, the regulations the FDA has developed for over the counter (OTC) sunscreen products apply to cosmetics, moisturizers, lip balms, and shampoos labeled with SPF values.
Table I: Experimental Conditions
Results
Conclusion
The methodology in Figure 1 provides one test method to determine both UVA and UVB compounds most commonly used in the sun care industry. Figure 2 is a sun care spray run with the same analytical conditions eluting six UVA/B compounds. All UVB and UVA compounds are eluted in a single run and can be quantitated in the ranges recommended by the FDA (SPF 15–50+). Only broad spectrum products with an SPF value of 15 or higher can claim to reduce the risk of skin cancer and early skin aging if used as directed with other sun protection measures.
Figure 1: All UVA and UVB compounds are eluted in a single run using a Brownlee SPP column with an optimized PerkinElmer HPLC system
Figure 2: SPF 50 sun care spray shows elution of both UVA/B compounds.
References
(1) U.S. Food and Drug Administration, 2012. Information for Consumers, 2012. Retrieved from http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingOver-the-CounterMedicines/ucm258468.htm.
PerkinElmer
940 Winter Street, Waltham, MA 02451
Tel. (800) 762-4000, fax (203) 944-4904
Website: www.perkinelmer.com
Top-down characterization of engineered Bcl-xL proteoforms
October 11th 2024Top-down fragmentation enables rapid characterization of phosphorylated proteins without extensive sample preparation and digestion. In this study, electron capture dissociation (ECD) was used to fragment proteoforms of the cell death-related protein, Bcl-xL. Using these methods, 85–90% sequence coverage was achieved for Bcl-xL proteoforms, allowing for effective localization of phosphorylation within minutes.
Antibody peptide mapping using the new Agilent ExD cell
October 11th 2024Enhanced antibody analysis using electron capture dissociation (ECD) allows for precise glycan localization in low-abundance glycopeptides. This study compares the fragmentation of trastuzumab tryptic digests using ECD and collision-induced dissociation (CID). While CID generates abundant glycan HexNAc ions at 204 m/z, ECD preserves the labile glycan group, enabling accurate site localization.
Identification of Amino Acid Isomers Using Electron Capture Dissociation
October 11th 2024Electron capture dissociation produces distinct fragments of amino acid side chains, enabling the identification of isomeric amino acids such as leucine and isoleucine. This application note demonstrates the isomer identification workflow for peptides and intact proteins using the new Agilent ExD cell and ExDViewer software for fragment analysis.
Trends, Best Practices, and Analytical Challenges in Chemical Characterization of Medical Devices
October 7th 2024Chemical characterization of medical devices, including drug-device combination products, is crucial for ensuring regulatory compliance and patient safety by identifying and quantifying chemicals that may interact with the human body. This paper explores current trends, best practices, and regulatory developments in extractables and leachables (E&L) testing for medical devices.
